Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pervasive Developmental Disability - Not Otherwise Specified Clear all
Completed Phase 2 Interventional Results available

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

NCT01592747
View directory record Official record
Conditions
Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl), Placebo capsules
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
64
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jul 21, 2026, 5:37 PM EDT
Completed Phase 1 Interventional

Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

NCT00773812
View directory record Official record
Conditions
Autistic Disorder, Pervasive Developmental Disorder
Interventions
mecamylamine, placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
4 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jul 21, 2026, 5:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Psychotherapy for Anxiety in Children With Autism Spectrum Disorder

NCT02028247
View directory record Official record
Conditions
Autism Spectrum Disorders, Autism, Asperger's Syndrome, Pervasive Developmental Disability - Not Otherwise Specified, Obsessive-compulsive Disorder, Social Phobia, Generalized Anxiety Disorder, Specific Phobia, Separation Anxiety Disorder
Interventions
Personalized Cognitive-behavioral therapy, Standard Practice Cognitive-behavioral therapy, Treatment as Usual
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
7 Years to 13 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Jul 21, 2026, 5:37 PM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Jul 21, 2026, 5:37 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Mitochondrial Dysfunction in Autism Spectrum Disorder

NCT02000284
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, Mitochondrial Disease, Developmental Delay
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
0 Years to 17 Years
Enrollment
297 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 21, 2026, 5:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety

NCT01919970
View directory record Official record
Conditions
Autism, Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified, Generalized Anxiety Disorder, Social Phobia, Separation Anxiety Disorder, Obsessive-compulsive Disorder, Specific Phobia
Interventions
Cognitive Behavioral Therapy, Treatment as usual
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 12 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jul 21, 2026, 5:37 PM EDT
Terminated Phase 3 Interventional

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

NCT01706523
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
STX209 (arbaclofen)
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
5 Years to 21 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Jul 21, 2026, 5:37 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592773
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
68
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Jul 21, 2026, 5:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism

NCT01563003
View directory record Official record
Conditions
Autism, Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified, Generalized Anxiety Disorder, Social Phobia, Separation Anxiety Disorder, Obsessive-compulsive Disorder
Interventions
Cognitive Behavioral Therapy, Treatment as usual
Other
Lead sponsor
University of South Florida
Other
Eligibility
11 Years to 16 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Jul 21, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

NCT00709202
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Betahistine, Placebo Oral Tablet
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 21, 2026, 5:37 PM EDT
Active, not recruiting No phase listed Observational

Genetic Contributions to Autism Spectrum Disorders

NCT01160783
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, Asperger's Syndrome, Pervasive Developmental Disorder
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Months and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 5:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents

NCT01177969
View directory record Official record
Conditions
Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified
Interventions
Cognitive-Behavioral Therapy, Wait-list
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
11 Years to 14 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
2
States / cities
Los Angeles, California • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Jul 21, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders

NCT00453180
View directory record Official record
Conditions
Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 12 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 21, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592786
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
72
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Jul 21, 2026, 5:37 PM EDT
Active, not recruiting No phase listed Observational

Phenotypic and Genetic Factors in Autism Spectrum Disorders

NCT00910559
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Months and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jul 21, 2026, 5:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Autism Spectrum Disorders (ASD) Characterization Study

NCT00801554
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Jul 21, 2026, 5:37 PM EDT